Stay updated with breaking news from Wildon Farwell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dyne Therapeutics (NASDAQ:DYN – Free Report) had its price target boosted by Jefferies Financial Group from $36.00 to $42.00 in a research note released on Monday, Benzinga reports. Jefferies Financial Group currently has a buy rating on the stock. DYN has been the topic of several other research reports. Morgan Stanley assumed coverage on Dyne […]
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - - DYNE-101 Showed Improvement in Myotonia,...
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - ...
Dyne Therapeutics (NASDAQ:DYN – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. They currently have a $36.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 38.04% from the company’s […]
Morgan Stanley started coverage on shares of Dyne Therapeutics (NASDAQ:DYN – Get Free Report) in a report released on Tuesday, Briefing.com reports. The firm set an “overweight” rating and a $40.00 price target on the stock. Morgan Stanley’s price target indicates a potential upside of 57.11% from the company’s previous close. A number of other […]